The main goal of the Program Grant is to obtain a deeper understanding of the immunobiology of nonmyeloablative allogeneic hematopoietic cell transplantation with or without concomitant organ transplantation such that a state of immune tolerance can be achieved. The Program Project has one clinical project (Project 1) (S. Strober, Leader) that will attempt to induce immune tolerance to HLA haplotype matched combined kidney and hematopoietic cell transplants by altering the balance of residual host T cells with the non-myeloablative conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (ATG). Project 2, (J. Shizuru, Leader), will perform new preclinical studies of TLI and ATG to investigate the cellular basis by which this conditioning regimen promotes the engraftment of hematopoietic stem cells. Project 3 (R. S. Negrin, Leader) will perform additional preclinical studies that elucidate the function of donor CD4+CD25+ Treg cells and show how they can be used more effectively to prevent GVHD while maintaining graft anti-tumor (GVT) activity. The interactions between donor T cells and subsets of host antigen presenting cells defined in Projects 1 and 4 will be determined also. Project 4 (E. Engleman, Leader) studies the mechanisms by which different subsets of host antigen presenting cells including dendritic cells activate and interact with different subsets of donor T cells including CD4+CD25+ regulatory T cells and Thi and Th2 conventional T cells. Core A (S. Strober, Leader) will provide statistical and administrative assistance to all Projects. Core B (R. Lowsky, Leader) will perform all human donor cell collections and cell purifications for purposes of transplantation into patients in Project 1, and will provide whole or purified subsets of peripheral blood mononuclear cells (PBMCs) from recipients, donors and controls to Projects 1, 2, and 4 and to Core C. Core C (E. Engleman, Leader) will provide immune monitoring assays of lymphocyte function as well as gene microarray assays to Projects 1, 2, and 4.

Public Health Relevance

The results of the proposed studies are expected to allow for the discontinuation of immunosuppressive drugs in kidney transplant patients, and avoid cumulative drug side effects. The results are also expected to reduce the risk of graft versus host disease in patients given hematopoietic cell transplants to treat leukemia and lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL075462-09
Application #
8470680
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Welniak, Lisbeth A
Project Start
2003-12-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
9
Fiscal Year
2013
Total Cost
$1,792,386
Indirect Cost
$657,828
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Kawai, Tatsuo; Leventhal, Joseph; Wood, Kathryn et al. (2018) Summary of the Third International Workshop on Clinical Tolerance. Am J Transplant :
Scandling, John D; Busque, Stephan; Lowsky, Robert et al. (2018) Macrochimerism and clinical transplant tolerance. Hum Immunol 79:266-271
Hongo, David; Tang, Xiaobin; Zhang, Xiangyue et al. (2017) Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129:1718-1728
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Simonetta, Federico; Alvarez, Maite; Negrin, Robert S (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol 8:465
Zhang, Hong; Gregorio, Josh D; Iwahori, Toru et al. (2017) A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc Natl Acad Sci U S A 114:1988-1993
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Pierini, Antonio; Nishikii, Hidekazu; Baker, Jeanette et al. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun 8:15068
Mavers, Melissa; Maas-Bauer, Kristina; Negrin, Robert S (2017) Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 8:900
Revelo, Xavier S; Ghazarian, Magar; Chng, Melissa Hui Yen et al. (2016) Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Rep 16:717-30

Showing the most recent 10 out of 70 publications